Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Arcturus Therapeutics Holdings Inc.

CIK 1768224Updated Nov 19, 2026

ARCT price & chart

Provider market data

Loading TradingView…

NASDAQ:ARCT on TradingView ↗

TradingView · Data may be delayed

About the company

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus’ strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes programs in cystic fibrosis (CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive…

8-K · 2026-11-16 · 0001193805-26-001485

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Seeking Alpha

Financials

FY 2025 · USD
Revenue82,031,000USD · FY 2025
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

Net income-65,783,000USD · FY 2025
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

Operating income-76,260,000USD · FY 2025
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

Diluted EPS-2.4USD per share · FY 2025
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ3 2025Q3 2024Q2 2026Q2 2025Q2 2024Q1 2026Q1 2025Q1 2024FY 2025FY 2024FY 2023FY 2022
ASSETS
AssetsUSD282,343,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

370,654,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

224,310,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

309,270,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

388,608,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

245,411,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

331,785,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

418,849,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

271,148,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

344,069,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

429,402,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

450,387,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Property, Plant and Equipment, NetUSD7,419,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

10,350,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

5,363,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

8,088,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

11,182,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

6,078,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

8,867,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

11,763,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

6,736,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

9,531,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

12,427,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

12,415,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD180,360,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

237,178,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2024-09-30

191,483,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

196,467,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2025-06-30

260,329,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2024-06-30

211,375,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

216,948,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2025-03-31

288,396,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2024-03-31

230,909,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

237,028,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

292,005,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

391,883,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Accounts Receivable, after Allowance for Credit Loss, CurrentUSD7,951,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

30,199,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

1,813,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

17,204,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

24,085,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

1,343,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

14,572,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

27,057,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

5,564,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

3,974,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

32,064,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

2,764,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Assets, CurrentUSD249,200,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

330,821,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

197,161,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

274,503,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

347,008,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

216,882,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

278,794,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

375,788,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

241,446,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

305,979,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

386,590,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

403,333,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Operating Lease, Right-of-Use AssetUSD23,839,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

27,598,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

19,758,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

24,794,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

28,533,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

20,423,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

25,739,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

29,413,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

21,081,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

26,674,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

28,500,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

32,545,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD57,784,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

108,788,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

52,502,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

78,217,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

130,025,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

54,049,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

98,026,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

154,877,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

57,163,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

103,091,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

150,889,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

180,075,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD27,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

27,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

28,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

27,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

27,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

28,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

27,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

27,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

28,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

27,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

27,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

27,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Additional Paid in CapitalUSD710,043,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

680,641,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

737,119,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

703,089,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

670,455,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

732,888,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

696,615,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

658,628,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

728,547,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

689,758,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

646,352,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

608,426,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Retained Earnings (Accumulated Deficit)USD-485,511,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

-418,802,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

-565,339,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

-472,063,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

-411,899,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

-541,554,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

-462,883,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

-394,683,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

-514,590,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

-448,807,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

-367,866,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

-338,141,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Stockholders' Equity Attributable to ParentUSD224,559,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

261,866,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2024-09-30

171,808,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

231,053,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2025-06-30

258,583,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2024-06-30

191,362,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

233,759,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2025-03-31

263,972,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2024-03-31

213,985,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

240,978,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

278,513,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

270,312,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Liabilities and EquityUSD282,343,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

370,654,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

224,310,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

309,270,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

388,608,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

245,411,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

331,785,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

418,849,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

271,148,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

344,069,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

429,402,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

450,387,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Current liabilities:
Liabilities, CurrentUSD31,699,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

69,463,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

33,536,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

46,515,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

91,717,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

34,369,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

49,409,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

115,430,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

36,379,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

65,489,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

81,989,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

126,984,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Operating Lease, Liability, CurrentUSD4,122,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

3,435,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

3,967,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

4,031,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

3,917,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

4,307,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

3,671,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

4,270,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

4,214,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

3,552,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

4,309,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

3,884,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Accounts Payable, CurrentUSD5,491,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

10,131,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

4,414,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

10,623,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

13,905,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

4,093,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

6,179,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

9,144,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

4,235,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

7,194,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

5,279,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

7,449,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Operating Lease, Liability, NoncurrentUSD21,865,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

25,987,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

18,966,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

22,933,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

26,964,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

19,680,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

23,987,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

27,652,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

20,784,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

24,998,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

25,907,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

30,216,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Other Liabilities, NoncurrentUSD——————————497,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

2,804,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD19,382,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

32,396,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

22,846,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

24,629,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

35,450,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

22,666,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

30,559,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

34,770,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

23,898,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

38,781,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

31,881,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

30,232,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Deferred Revenue, CurrentUSD6,826,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

26,936,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

6,276,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

11,263,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

42,362,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

7,610,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

12,671,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

71,516,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

8,246,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

19,514,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

44,829,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

28,648,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Deferred Revenue, NoncurrentUSD4,220,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

13,338,000
Source

10-Q · 2024-11-07 · 0000950170-24-123469

As of 2024-09-30

—8,769,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

As of 2025-06-30

11,344,000
Source

10-Q · 2024-08-05 · 0000950170-24-090905

As of 2024-06-30

—9,630,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

11,795,000
Source

10-Q · 2024-05-08 · 0000950170-24-055702

As of 2024-03-31

—12,604,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

42,496,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

20,071,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Long-term Debt, Current MaturitiesUSD———————————60,655,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Long-term Debt, Excluding Current Maturities———————
Source

10-Q · 2025-05-12 · 0000950170-25-069210

As of 2025-03-31

—————

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization———
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

—
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

—
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

—
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

—
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

—
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

—
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

—
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

—
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

—
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Share-based Payment Arrangement, Noncash ExpenseUSD——————4,325,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

6,662,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

25,408,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

37,988,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

34,649,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

30,611,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts ReceivableUSD——————-4,221,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

10,598,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

1,590,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-28,090,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

29,300,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-603,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Increase (Decrease) in Accounts PayableUSD——————-142,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-1,015,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-2,959,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

1,915,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-2,238,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-3,112,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD——————-19,441,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-35,138,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-74,271,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-59,747,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-18,099,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

31,993,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD——————34,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-137,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-230,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-648,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-2,901,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-7,726,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Payments to Acquire Property, Plant, and EquipmentUSD——————0
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

137,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

230,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

648,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

2,901,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

7,726,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD——————16,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

15,195,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

13,382,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

5,418,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-24,087,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-2,859,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD——————-19,391,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-20,080,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-61,119,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-54,977,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-45,087,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

21,408,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD——237,245,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2025-09-30

294,063,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

As of 2024-09-30

193,511,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2026-06-30

253,352,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

As of 2025-06-30

213,403,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2026-03-31

273,833,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

As of 2025-03-31

232,794,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

As of 2025-12-31

293,913,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

As of 2024-12-31

348,890,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

As of 2023-12-31

393,977,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

As of 2022-12-31

Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD——————————2,127,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

813,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Income Taxes Paid, NetUSD—————————1,407,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

——
Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD——5,729,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

9,493,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

4,231,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

6,200,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

4,325,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

6,662,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

25,408,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

37,988,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

34,649,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

30,611
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD——-170,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-201,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

—-127,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

2025-04-01 to 2025-06-30

—-21,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

2025-01-01 to 2025-03-31

382,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-471,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-229,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-598,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), RealizedUSD——————-1,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-21,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-382,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-471,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-90,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-375,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Gain (Loss) on Extinguishment of DebtUSD——————————33,953,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

—
General and Administrative ExpenseUSD——10,398,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

13,276,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

10,989,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

10,338,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

9,465,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

11,315,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

46,079,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

52,823,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

52,871,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

46,071,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Goodwill, Impairment LossUSD————————0
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

0
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

0
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

0
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Income (Loss) from Equity Method InvestmentsUSD———————————-515,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Income Tax Expense (Benefit)USD———-217,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

0
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

4,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

—0
Source

10-Q · 2025-05-12 · 0000950170-25-069210

2025-01-01 to 2025-03-31

—-4,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

1,835,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

1,295,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Net Income (Loss) Attributable to ParentUSD——-13,448,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-6,903,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-23,785,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-9,180,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

-26,964,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-14,076,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-65,783,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-80,941,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-29,725,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

9,349,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Operating ExpensesUSD——33,663,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

52,410,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

28,504,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

39,917,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

30,992,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

46,208,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

158,291,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

247,979,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

245,004,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

193,822,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Operating Lease, Impairment LossUSD————————1,897,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

———
Other Nonoperating Income (Expense)USD——3,234,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

3,818,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-59,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-127,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

35,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-21,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

10,095,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

15,195,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

16,591,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-420,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Proceeds from Issuance of Common StockUSD————————11,688,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

———
Proceeds from Stock Options ExercisedUSD——————16,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

195,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

1,109,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

4,736,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

2,668,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

1,730,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Gain (Loss) on Disposition of Property Plant Equipment———————
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

—
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

————

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024FY 2023FY 2022
Total RevenueUSD——17,151,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

41,673,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

2,959,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

28,301,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

2,061,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

29,382,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

82,031,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

152,310,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

166,799,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

205,999,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Operating Income (Loss)USD——-16,512,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-10,737,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-25,545,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-11,616,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

-28,931,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-16,826,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-76,260,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-95,669,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-78,205,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

12,177,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Other Nonoperating Income (Expense)USD——3,234,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

3,818,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-59,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-127,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

35,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-21,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

10,095,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

15,195,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

16,591,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-420,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD——-13,448,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-7,120,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-23,785,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-9,176,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

—-14,076,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

2025-01-01 to 2025-03-31

-65,783,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-80,945,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-27,890,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

10,644,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Income Tax Expense (Benefit)USD———-217,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

0
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

4,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

—0
Source

10-Q · 2025-05-12 · 0000950170-25-069210

2025-01-01 to 2025-03-31

—-4,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

1,835,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

1,295,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Net Income (Loss) Attributable to ParentUSD——-13,448,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-6,903,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-23,785,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-9,180,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

-26,964,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-14,076,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-65,783,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-80,941,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-29,725,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

9,349,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Earnings Per Share, BasicUSD per share——-0.49
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-0.26
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-0.84
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-0.34
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

-0.95
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-0.52
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-2.4
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-3
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-1.12
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

0.35
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Earnings Per Share, DilutedUSD per share——-0.49
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-0.26
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

-0.84
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

-0.34
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

-0.95
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-0.52
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-2.4
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-3
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-1.12
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

0.35
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Basicshares——27,188,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

27,062,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

28,423,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

27,129,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

28,421,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

27,107,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

27,386,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

27,000,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

26,628,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

26,445,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares——27,188,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

27,062,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

28,423,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

27,129,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

28,421,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

27,107,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

27,386,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

27,000,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

26,628,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

27,093,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Additional Financial Items
Current Income Tax Expense (Benefit)USD—————————-4,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

1,835,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

1,295,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Depreciation, Depletion and Amortization, NonproductionUSD——800,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

900,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

600,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

800,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

658,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

801,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

3,025,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

3,544,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

2,957,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

1,527,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD——-170,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

-201,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

—-127,000
Source

10-Q · 2025-08-11 · 0000950170-25-106560

2025-04-01 to 2025-06-30

—-21,000
Source

10-Q · 2025-05-12 · 0000950170-25-069210

2025-01-01 to 2025-03-31

382,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-471,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-229,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-598,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Foreign Currency Transaction Gain (Loss), RealizedUSD——————-1,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

-21,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

-382,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

-471,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-90,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

-375,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

General and Administrative ExpenseUSD——10,398,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

13,276,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

10,989,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

10,338,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

9,465,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

11,315,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

46,079,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

52,823,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

52,871,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

46,071,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Goodwill, Impairment LossUSD————————0
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

0
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

0
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

0
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD————————-65,783,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

81,050,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

-27,890,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

10,644,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Income (Loss) from Equity Method InvestmentsUSD———————————-515,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Operating ExpensesUSD——33,663,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

52,410,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

28,504,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

39,917,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

30,992,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

46,208,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

158,291,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

247,979,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

245,004,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

193,822,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Research and Development ExpenseUSD——23,265,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2025-07-01 to 2025-09-30

39,134,000
Source

10-Q · 2025-11-12 · 0001193125-25-275758

2024-07-01 to 2024-09-30

17,515,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2026-04-01 to 2026-06-30

29,579,000
Source

10-Q · 2026-08-06 · 0001193125-26-338090

2025-04-01 to 2025-06-30

21,527,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2026-01-01 to 2026-03-31

34,893,000
Source

10-Q · 2026-05-07 · 0001193125-26-211943

2025-01-01 to 2025-03-31

112,212,000
Source

10-K · 2026-03-03 · 0001193125-26-088391

2025-01-01 to 2025-12-31

195,156,000
Source

10-K · 2025-03-06 · 0000950170-25-034787

2024-01-01 to 2024-12-31

192,133,000
Source

10-K · 2024-03-14 · 0000950170-24-031156

2023-01-01 to 2023-12-31

147,751,000
Source

10-K · 2023-03-29 · 0000950170-23-010380

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

e665891_ex99-1.htm · 8-K · 2026-11-16

Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration $50 Million Strategic Investment in Arcturus at an 80% Premium Proceeds to accelerate development of ARCT-2601 for OTC Deficiency and clinically validate Arcturus’ LUNAR 2.0™ next-generation mRNA platform SAN DIEGO--(BUSINESS WIRE) -- November 16, 2026 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the de…

8-K · 2026-11-16 · 0001193805-26-001485

Read attachment ↗
e665874_ex99-1.htm · 8-K · 2026-11-05

Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 enrollment completion YE 2026; data presentation Q2 2027 ARCT-2601 (OTC Deficiency), the first mRNA therapeutic candidate utilizing LUNAR 2.0™, Phase 2 dosing planned to begin Q1 2027; top-line data H2 2027 Investor conference call at 4:30 p.m. ET today SAN DIEGO--(BUSINESS WIRE) -- November 5, 2026 -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), …

8-K · 2026-11-05 · 0001193805-26-001439

Read attachment ↗
e665798_ex99-2.htm · 8-K · 2026-09-23

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP studies - unlocks new therapeutic opportunities ARCT-2601, an OTC deficiency therapeutic candidate utilizing LUNAR 2.0™, to be integrated by …

8-K · 2026-09-23 · 0001193805-26-001277

Read attachment ↗
e665679_ex99-1.htm · 8-K · 2026-08-06

EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026 Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released…

8-K · 2026-08-06 · 0001193805-26-001039

Read attachment ↗
e665618_ex99-1.htm · 8-K · 2026-07-02

EX-99.1 2 e665618_ex99-1.htm Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights SAN DIEGO, Calif. --(BUSINESS WIRE)--July 2, 2026--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today ann…

8-K · 2026-07-02 · 0001193805-26-000910

Read attachment ↗
e665435_ex99-1.htm · 8-K · 2026-05-07

EX-99.1 3 e665435_ex99-1.htm Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress Initiated enrollment (Q1 2026) earlier than expected for 12-week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine transcarbamylase (OTC) deficiency program; End of Phase 2 (EOP2) meeting H2 2026 Inve…

8-K · 2026-05-07 · 0001193805-26-000573

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.